Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2009 | 03-2009 | 12-2008 | 09-2008 | 06-2008 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 980 | 860 | 310 | 810 | 1,550 |
| Other current assets | 80 | 60 | 70 | 80 | 100 |
| TOTAL | $1,060 | $920 | $380 | $890 | $1,650 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 260 | 270 | 270 | 280 | 300 |
| TOTAL | $260 | $270 | $270 | $280 | $300 |
| Total Assets | $1,360 | $1,230 | $700 | $1,230 | $2,010 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 750 | 800 | 440 | 160 | 230 |
| Accrued Expenses | 590 | 510 | 430 | 340 | 410 |
| Other current liabilities | 0 | 0 | 200 | 200 | 20 |
| TOTAL | $1,350 | $1,310 | $1,070 | $700 | $670 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,360 | 1,560 | 90 | 900 | 2,050 |
| TOTAL | $2,360 | $1,560 | $90 | $900 | $2,050 |
| Total Liabilities | $3,710 | $2,880 | $1,170 | $1,610 | $2,730 |
| Shareholders' Equity | |||||
| Common Shares | 50 | 50 | 40 | 40 | 40 |
| Retained earnings | -44,490 | -41,150 | -38,550 | -37,680 | -37,700 |
| Other shareholders' equity | 1,690 | 1,170 | 730 | 720 | 710 |
| TOTAL | $-2,350 | $-1,640 | $-460 | $-380 | $-710 |
| Total Liabilities And Equity | $1,360 | $1,240 | $710 | $1,230 | $2,020 |